Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(2012) In Cancer Biotherapy & Radiopharmaceuticals 27(2). p.134-140- Abstract
- Abstract Aim: Fractionation is generally used as a mean to improve radioimmunotherapy (RIT). Since RIT is considered suitable for small-volume disease, the aim of the current study was to investigate whether repeated administration of (177)Lu-labeled mAb BR96 was tolerated and could delay or prevent metastatic disease after complete remission of the tumor obtained by the first administration. Methods: Immunocompetent rats bearing a syngeneic colon carcinoma were first treated with 400 MBq/kg (177)Lu-DOTA-BR96, an activity resulting in complete response in 29 of 30 animals. On day 21, two groups of rats were given an additional activity of 150 or 350 MBq/kg resulting in total administered activities corresponding to 0.9 and 1.3 times the... (More)
- Abstract Aim: Fractionation is generally used as a mean to improve radioimmunotherapy (RIT). Since RIT is considered suitable for small-volume disease, the aim of the current study was to investigate whether repeated administration of (177)Lu-labeled mAb BR96 was tolerated and could delay or prevent metastatic disease after complete remission of the tumor obtained by the first administration. Methods: Immunocompetent rats bearing a syngeneic colon carcinoma were first treated with 400 MBq/kg (177)Lu-DOTA-BR96, an activity resulting in complete response in 29 of 30 animals. On day 21, two groups of rats were given an additional activity of 150 or 350 MBq/kg resulting in total administered activities corresponding to 0.9 and 1.3 times the maximal tolerated dose. Results: The additional treatment resulted in tolerable myelotoxicity; however, the frequency of metastatic disease and survival were not affected. Immunohistochemistry demonstrated binding of the BR96 antibody to tissue sections of analyzed metastases. Conclusions: In our model, development of metastatic disease after treatment of the manifest tumor was not prevented by an additional treatment with the same radioimmunoconjugate. Therefore, the antibody should be labeled with a more suitable radionuclide for treatment of metastases. The repeated targeted therapy was well tolerated in aspects of myelotoxicity. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2336600
- author
- Eriksson, Sophie LU ; Ohlsson, Tomas G LU ; Nilsson, Rune LU and Tennvall, Jan LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- metastases, radioimmunotherapy, Lutetium-177, colon carcinoma, fractionation
- in
- Cancer Biotherapy & Radiopharmaceuticals
- volume
- 27
- issue
- 2
- pages
- 134 - 140
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- wos:000301440900005
- pmid:22229635
- scopus:84858432399
- pmid:22229635
- ISSN
- 1557-8852
- DOI
- 10.1089/cbr.2011.1080
- language
- English
- LU publication?
- yes
- id
- a91e0d76-6e9c-462e-9341-32fca6bc2ed8 (old id 2336600)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22229635?dopt=Abstract
- date added to LUP
- 2016-04-01 13:34:27
- date last changed
- 2022-01-27 19:53:05
@article{a91e0d76-6e9c-462e-9341-32fca6bc2ed8,
abstract = {{Abstract Aim: Fractionation is generally used as a mean to improve radioimmunotherapy (RIT). Since RIT is considered suitable for small-volume disease, the aim of the current study was to investigate whether repeated administration of (177)Lu-labeled mAb BR96 was tolerated and could delay or prevent metastatic disease after complete remission of the tumor obtained by the first administration. Methods: Immunocompetent rats bearing a syngeneic colon carcinoma were first treated with 400 MBq/kg (177)Lu-DOTA-BR96, an activity resulting in complete response in 29 of 30 animals. On day 21, two groups of rats were given an additional activity of 150 or 350 MBq/kg resulting in total administered activities corresponding to 0.9 and 1.3 times the maximal tolerated dose. Results: The additional treatment resulted in tolerable myelotoxicity; however, the frequency of metastatic disease and survival were not affected. Immunohistochemistry demonstrated binding of the BR96 antibody to tissue sections of analyzed metastases. Conclusions: In our model, development of metastatic disease after treatment of the manifest tumor was not prevented by an additional treatment with the same radioimmunoconjugate. Therefore, the antibody should be labeled with a more suitable radionuclide for treatment of metastases. The repeated targeted therapy was well tolerated in aspects of myelotoxicity.}},
author = {{Eriksson, Sophie and Ohlsson, Tomas G and Nilsson, Rune and Tennvall, Jan}},
issn = {{1557-8852}},
keywords = {{metastases; radioimmunotherapy; Lutetium-177; colon carcinoma; fractionation}},
language = {{eng}},
number = {{2}},
pages = {{134--140}},
publisher = {{Mary Ann Liebert, Inc.}},
series = {{Cancer Biotherapy & Radiopharmaceuticals}},
title = {{Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.}},
url = {{http://dx.doi.org/10.1089/cbr.2011.1080}},
doi = {{10.1089/cbr.2011.1080}},
volume = {{27}},
year = {{2012}},
}